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The Affordable Medicines Facility-malaria (AMFm) has put into place a bold financing plan for
artemisinin-combination therapy in a pilot phase in seven countries covering half the population at risk of malaria
in Africa. A report of the AMFm independent evaluation, conducted by ICF International and the London School of
Hygiene and Tropical Medicine, describes the success of the programme in the pilot sites: Ghana, Kenya,
Madagascar, Niger, Nigeria, Tanzania (mainland and Zanzibar) and Uganda, comparing availability and affordability
of high-quality artemisinin-combination therapies before and after AMFm launched. Proof of concept was achieved:
AMFm increased availability and kept prices low, meeting its initial, ambitious benchmarks in most settings. Despite
this overwhelming success, opposition to the programme and dwindling resources for malaria control conspire to
cripple or kill AMFm.
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AMFm began with an audacious idea first proposed in a
2004 U.S. Institute of Medicine expert report, Saving
Lives, Buying Time: Economics of Malaria Drugs in an
Age of Resistance [1]. The idea was to subsidize the
world’s most effective anti-malarial medicines at the top
of the supply chain—at the manufacturers’ factory gates.
The drugs would then flow to patients in the same
way older, now-ineffective, agents did (and still do).
The IOM committee settled on this recommendation to
accommodate these realities:
1. ACT, the WHO-recommended first-line medicine for
falciparum malaria, is much more costly than their
widely-available competitors, now largely ineffectual
because of drug resistance.
2. In Africa, anti-malarial medicines are more likely to
be purchased from private vendors than from public
clinics, which often have stock-outs.* Correspondence: atalisuna@nairobi.kemri-wellcome.org
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reproduction in any medium, provided the or3. Given their general unaffordability, minus a subsidy,
many shopkeepers would never stock ACT.
In 2008, the Global Fund to Fight AIDS, Tuberculosis
and Malaria assumed responsibility for AMFm in a
programme financially and administratively separate
from the Fund’s routine grant-making. The high-level
subsidy, a vigorous price negotiation conducted by the
Clinton Health Access Initiative (CHAI) and a suite of
‘supporting interventions’ were the centerpieces of what
was eventually named AMFm.
A pilot involving seven countries was supported by the
Roll Back Malaria Partnership, the World Bank and
others, including lead funders, the U.K. Department for
International Development, UNITAID, and the Bill &
Melinda Gates Foundation. Under the AMFm pilot, the
first ‘co-paid’ ACT was shipped to Ghana in August
2010 and the rest of the countries came on line over the
next eight months.Independent evaluation of the AMFm pilot
The Global Fund Board required a thorough evalua-
tion of the pilot that it could rely on to base decisions
about AMFm’s future. ICF International and the Londonl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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conducted the evaluation independent of the Global
Fund and AMFm. This is the first global public health
intervention to be evaluated against stringent bench-
marks agreed upon ahead of time [2] and it is among
the most thorough and costly such evaluation ever
undertaken.
In summary, the evaluation [3,4] reported:
‘Of the 8 pilots, success benchmarks were clearly met
in 5 pilots for availability, 5 pilots for QAACT
[quality-assured artemisinin-combination therapy]
price relative to the most popular antimalarial that is
not a QAACT, and 4 pilots for QAACT market
share. . .. It is also possible that benchmarks were met
in one additional pilot for availability and price, and
in 3 additional pilots for market share, although the
evidence is not as strong. . .. The success benchmarks
related to artemisinin monotherapy (AMT) price and
market share were met in all pilots with sufficient
AMT in the market to make these benchmarks
relevant.’
AMFm was, in the words of the evaluators, a ‘game
changer’ that brought ACT to the village.What comes next for AMFm
Because AMFm’s 18-month pilot was largely successful,
the global community should now be faced with the
happy task of expanding the programme. To wit: AMFm
phase 2 would reach even more countries and many
more poor and vulnerable people, and ACT would soon
be coupled with rapid diagnostic tests (RDTs) to ensure
that modern anti-malarial medicines are dispensed only
to patients with proven malaria and not those suffering
with febrile illnesses from other causes.
Instead, what is looming is that AMFm will either
scale down or end altogether. The Global Fund Board is
set to vote on AMFm’s future in November 2012, not
long before the pilot is set to conclude at the end of
2012. A transition period is planned if AMFm were not
to continue though the length of this transition period
and the level of support that would be available is not
fully clear.Discussion
As chloroquine resistance spread around the globe dur-
ing the end of the 20th century, malaria and child mor-
tality rates increased [5]. Even then, people still used
chloroquine because it was available and affordable.
ACT was neither available nor affordable in the private
sector until AMFm-subsidized packs reached the shelves
of shops and pharmacies through the AMFm pilot.No one denies that defeating malaria requires multiple
tools, including insecticide-treated nets, indoor spraying
of houses, and other vector control measures. But indis-
putably, the suite of interventions must also include
easily-accessed and effective medicines real people can
afford.
It is surprising to malaria control managers in Africa
that the donors who generously funded the AMFm pilot
would want to move on to other problems. Most health
professionals who have been fighting malaria in Africa
and have too often suffered from this old scourge agree
that money for malaria control must not be wasted. Nor
are they blind to other health needs. But AMFm has
worked where nothing else does, and even at scale, it
should be affordable globally if malaria continues to be
prioritized.
The successes of insecticide-treated nets have been
trumpeted by several stakeholders [6]. But relative to the
problem, the successes are modest. The malaria burden
has not, for instance, been halved. If the global commu-
nity does not persevere with all control measures, well-
documented history says the gains made will surely be
lost [7]. An important part of continuing to make
inroads in the malaria burden is expanding—not con-
tracting—access to high-quality ACT for all who need it.
Now, as has been the case for decades, and as the IOM
committee observed, the private sector is a
complimentary and important supplier of medicines for
malaria in most settings in Africa.Conclusions
AMFm has proven itself and should be expanded to in-
clude more countries and adapted as needed to the
changing malaria landscape and country specific context.
This may mean finding ways of encouraging the use of
RDTs, for instance. But the basic architecture of the
AMFm subsidy and price negotiations should continue
and expand. The evidence supports AMFm and the cost
is not prohibitive for what it delivers. The $300 million
spent on the pilot is a mere fraction of the $30 billion or
so of the health development aid spent around the world
each year [8]. The credibility of the international com-
munity in Africa is at stake. AMFm should be a global
priority, not merely an interesting footnote of malaria
control history.
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